A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
NASH
Interventions
DRUG

Lang Qingata

Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use,2 times/day, 4 weeks for a course of treatment.

DRUG

placebo

Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata,Decoction in water for oral use

Trial Locations (1)

210000

RECRUITING

A multicenter, double-blind, placebo-randomized controlled clinical study on the treatment of non-alcoholic steatohepatitis with Tibetan drug Langqing Atta, Nanjing

All Listed Sponsors
lead

Shupei Li

OTHER